LIVN Earnings

LIVN reported its earnings on 2026-02-25, showcasing a revenue of against an estimate of 350.93M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.8 by 0%. The stock experienced a 1.8% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following LIVN's earnings announcement on 2026-02-25, the stock price moved by 1.8% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, LIVN's stock price tends to shift by an average of -1.98% in the 10 days leading up to earnings and 0.13% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate LIVN's annual revenue to reach 339.13M, while the EPS is projected at 0.89. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.08% over the past three months, indicating analyst expectation in the company's performance.

The correlation between LIVN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.08%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LIVN's stock price typically moves by -1.98% in the 10 days before its earnings and 0.13% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.89 and revenue of 339.13M.

The earnings call summary highlights increased guidance across multiple financial metrics, including revenue and EPS, alongside strategic growth in cardiopulmonary and epilepsy segments. The Q&A section reveals positive analyst sentiment and confidence in management's ability to execute on guidance, with no major risks identified. The company's proactive approach to reimbursement changes and product launches further supports a positive outlook. Despite conservative assumptions for 2026, the current guidance and market strategy suggest a likely positive stock price movement in the near term.